Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database.

ABSTRACT:

Introduction

The development of Janus kinase (JAK) inhibitors has significantly expanded the therapeutic options for patients with psoriasis and psoriatic arthritis (PsA). However, the distinct pharmacological profiles and target selectivity of these agents result in varying safety implications. This study systematically evaluates the safety of different JAK inhibitors in psoriasis and PsA patients.

Methods

A retrospective pharmacovigilance study was conducted using the Food and Drug Administration Adverse Event Reporting System (FAERS) database. The disproportionality analysis methods, including reporting odds ratio (ROR) and information component (IC), were used to evaluate the adverse events (AEs) associated with the use of JAK inhibitors (deucravacitinib, upadacitinib, t

SUBMITTER: Deng K 

PROVIDER: S-EPMC12529101 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature